MustGrow Biologics (MGROF)
OTHER OTC:MGROF

MustGrow Biologics (MGROF) Income Statement

10 Followers

MustGrow Biologics Income Statement

Last quarter (Q4 2023), MustGrow Biologics's total revenue was C$―, a decrease of ― from the same quarter last year. In Q4, MustGrow Biologics's net income was C$-1.03M. See MustGrow Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
C$ 4.71MC$ 4.71MC$ 6.48KC$ 12.87KC$ 0.00C$ 0.00
Cost of Revenue
------
Gross Profit
C$ 4.71MC$ 4.71MC$ 6.48K---
Operating Expense
C$ 5.53MC$ 5.52MC$ 5.69MC$ 3.02MC$ 3.37MC$ 1.47M
Operating Income
C$ -812.83KC$ -804.99KC$ -5.69MC$ -3.01MC$ -3.37MC$ -1.47M
Net Non Operating Interest Income Expense
C$ 216.86KC$ 211.60KC$ 93.48KC$ 52.77KC$ -45.87KC$ -45.88K
Other Income Expense
----C$ 105.19K-
Pretax Income
C$ -665.05KC$ -676.94KC$ -5.57MC$ -3.06MC$ -3.31MC$ -1.52M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
C$ -665.05KC$ -676.94KC$ -5.57MC$ -3.06MC$ -3.31MC$ -1.52M
Basic EPS
C$ >-0.01C$ -0.01C$ -0.11C$ -0.07C$ -0.09C$ -0.06
Diluted EPS
C$ >-0.01C$ -0.01C$ -0.11C$ -0.07C$ -0.09C$ -0.06
Basic Average Shares
C$ 201.36MC$ 49.89MC$ 49.01MC$ 43.74MC$ 37.31MC$ 25.29M
Diluted Average Shares
C$ 201.36MC$ 49.89MC$ 49.01MC$ 43.74MC$ 37.31MC$ 25.29M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
C$ 4.40M-C$ 5.69MC$ -3.02MC$ 3.37MC$ 1.47M
Net Income From Continuing And Discontinued Operation
C$ -665.05KC$ -676.94KC$ -5.57MC$ -3.06MC$ -3.31MC$ -1.52M
Normalized Income
C$ -752.62KC$ -497.55KC$ -4.09MC$ -2.25MC$ -3.42MC$ -1.52M
Interest Expense
----C$ 45.87KC$ 45.88K
EBIT
C$ -665.05KC$ -676.94KC$ -5.56MC$ -3.01MC$ -3.26MC$ -1.47M
EBITDA
C$ -665.05KC$ -676.94KC$ -5.56MC$ -3.01MC$ -3.26MC$ -1.47M
Currency in CAD

MustGrow Biologics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis